- Completes Acquisition of Osteocel Biologics Business from Osiris Therapeutics - - Increases 2008 Revenue Guidance to $238 to $240 Million, including $15 Million in Osteocel Revenue -
SAN DIEGO, July 24 /PRNewswire-FirstCall/ -- NuVasive, Inc. (Nasdaq:
NUVA), a medical device company focused on developing products for minimally
disruptive surgical treatments for the spine, announced today financial
results for the quarter ended June 30, 2008.
NuVasive reported second quarter revenues of $57.4 million, a 61.2%
increase over the $35.6 million for the second quarter of 2007 and a 12.2%
increase over the $51.2 million for the first quarter of 2008.
Gross profit for the second quarter of 2008 was $47.8 million and gross
margin was 83.3%, compared to a gross profit of $28.9 million and a gross
margin of 81.2% in the second quarter of 2007. For the first quarter of 2008,
gross profit was $42.1 million and gross margin was 82.2%.
Total operating expenses for the second quarter of 2008 were $48.5 million
compared to $34.0 million in the second quarter of 2007 and $50.5 million in
the first quarter of 2008. First quarter 2008 operating expenses included an
in-process research and development charge of $4.2 million, or ($0.12) per
diluted share related to the acquisition of pedicle screw intellectual
property. Excluding the in-process research and development charge, total
first quarter 2008 operating expenses were $46.3 million.
On a GAAP basis, the Company reported a net loss of $0.5 million or
$(0.01) per share for the second quarter of 2008. On a non-GAAP basis, the
Company reported net income of $5.1 million, or $0.14 per share, for the
second quarter of 2008. The non-GAAP earnings per share calculations exclude
(i) stock based compensation of $5.1 million and (ii) amortization of acquired
intangible assets of $0.5 million.
Cash, cash equivalents and short and long-term investments were $265.7
million at June 30, 2008.
On July 24th, 2008, NuVasive completed its previously announced
acquisition of the Osteocel biologics business from Osiris Therapeutics. The
Osteocel business includes a proprietary adult stem cell bone graft product
which is the only viable bone matrix product on the market that provides the
three beneficial properties similar to autograft: osteoconduction (provides a
scaffold for bone growth), osteoinduction (bone formation stimulation) and
osteogenesis (bone production).
Alex Lukianov, Chairman and Chief Executive Officer, said, "Our robust
results in the second quarter were driven by the continued maturation of our
exclusive sales force and its growing expertise in selling the full mix of our
innovative product portfolio. We also successfully executed on several
components of our growth strategy. These included the recent closing of the
Osteocel acquisition, conversion of our enterprise software platform and the
continued enrollment of our NeoDisc clinical trial, which we expect to
complete in August 2008. In addition, we completed our planned expansion of
our cervical product offering with the full national launch of our Helix Mini
Plate and VuePoint posterior system."
Mr. Lukianov continued, "We are pleased to complete the acquisition of the
Osteocel biologics business, which represents a significant milestone in our
strategy to expand our product portfolio with synergistic and innovative
technologies. We believe there is substantial opportunity to create an
aggressive marketing program to achieve this product's full potential and,
combined with our Formagraft product, we look to create a $100 million
biologics business over the next several years."
Mr. Lukianov added, "We continue to execute on our strategic objectives,
including rapid product development, advancement of our MAS platform,
continued adoption of our XLIF procedure, and significant expansion of our
operating infrastructure. These initiatives are key to our long term growth
and ability to continue increasing our market share. We are committed to
advancing all of these objectives in concert with robust revenue growth and
expanding profitability. Although global economic conditions have resulted in
increased expenses relating to items such as shipping, distribution, and
travel, coupled with lower yields on cash investments, we remain committed to
GAAP profitability as demonstrated by our increased earnings guidance for the
second half of 2008. Our shareowners are dedicated to making NuVasive a major
force in the spine industry."
Updated 2008 Financial Guidance
NuVasive is updating its full year 2008 financial guidance as follows:
Revenue:
- $238 million to $240 million, including $15 million in Osteocel; up
from previous guidance of $210 million to $214 million
Gross margin:
- 80% to 81%, down from previous guidance of 81% to 82%, which reflects
gross margin from Osteocel sales
EPS:
- GAAP: $(0.61) to $(0.45), including $(0.66) to $(0.52) of one-time
charges
- Excluding one-time charges, earnings per share $0.05 to $0.07;
up from $0.00 to $0.03
- Non-GAAP: $0.68 to $0.70; up from $0.54 to $0.57
Reconciliation of Non-GAAP Information
Management uses certain non-GAAP financial measures such as non-GAAP
earnings per share, which exclude stock based compensation and charges
directly related to acquisition transactions such as in-process research and
development, milestone payments, and amortization of the acquired technology
assets. Management does not consider these costs in evaluating the continuing
operations of the Company. Therefore, management calculates the non-GAAP
financial measures provided in this earnings release excluding these costs and
uses these non-GAAP financial measures to enable it to analyze further and
more consistently the period-to-period financial performance of its core
business operations. Management believes that providing investors with these
non-GAAP measures gives them additional important information to enable them
to assess, in the same way management assesses, the Company's current and
future continuing operations. These non-GAAP measures are not in accordance
with, or an alternative for, GAAP, and may be different from non-GAAP measures
used by other companies. Set forth below are reconciliations of the non-GAAP
financial measures to the comparable GAAP financial measure.
Reconciliation of Second Quarter 2008 Results
(in thousands, except per share amounts)
GAAP net loss (A) $(495)
Stock-based compensation (B) 5,148
Amortization of acquired intangible assets (C) 467
Non-GAAP earnings (A) $5,120
GAAP net loss per share (A) $(0.01)
Stock-based compensation (B)0.14
Amortization of acquired intangible assets (C) 0.01
Non-GAAP earnings per share (A)$0.14
Shares used in computing GAAP net loss per share (A) 35,663
Share used in computing non-GAAP net loss per share (A) 37,425
Reconciliation of Full Year 2008 GuidanceRange for Year Ending
December 31, 2008
(in thousands, except per share amounts) Low High
GAAP net loss per share (A) $(0.61) $(0.45)
One-time charges (D) 0.66 0.52
Earnings per share excluding one-time charges 0.05 0.07
Stock-based compensation (B) 0.56 0.52
Amortization of acquired intangible assets (D)0.09 0.09
Non-GAAP earnings per share (A) $0.70 $0.68
Shares used in computing GAAP net
loss per share (A) 35,80835,808
Share used in computing non-GAAP net
loss per share (A) 37,64137,641
A - GAAP net loss per share is calculated using basic weighted shares
outstanding; Non-GAAP earnings per share is calculated using diluted
weighted shares outstanding.
B - Non-cash stock-based compensation
C - Amortization of purchased technology assets.
D - One-time charges related to the acquisition of pedicle screw
technology in the first quarter of 2008 and the pending acquisition of
the Osteocel business.
Conference Call
NuVasive will hold a conference call today at 5:30 p.m. ET / 2:30 p.m. PT
to discuss the results. The dial-in numbers are 1-877-407-4018 for domestic
callers and 1-201-689-8471 for international. A live Web cast of the
conference call will be available online from the investor relations page of
the Company's corporate Web site at www.nuvasive.com.
After the live Web cast, the call will remain available on NuVasive's Web
site, www.nuvasive.com, through August 24, 2008. In addition, a telephonic
replay of the call will be available until August 14, 2008. The replay
dial-in numbers are 1-877-660-6853 for domestic callers and 1-201-612-7415 for
international callers. Please use account number 3055 and conference ID
number 289122.
About NuVasive
NuVasive is a medical device company focused on the design, development
and marketing of products for the surgical treatment of spine disorders. The
Company's product portfolio is focused on applications in the over $4.2
billion U.S. spine fusion market. The Company's current principal product
offering includes a minimally disruptive surgical platform called Maximum
Access Surgery, or MAS(R), as well as a growing offering of cervical and
motion preservation products.
The MAS platform offers advantages for both patients and surgeons such as
reduced surgery and hospitalization time and faster recovery. MAS combines
three categories of current product offerings: NeuroVision(R) a proprietary
software-driven nerve avoidance system; MaXcess(R) a unique split-blade design
retraction system; and specialized implants, like SpheRx(R) and CoRoent(R),
that collectively minimize soft tissue disruption during spine surgery while
allowing maximum visualization and surgical reproducibility. NuVasive's
product offering is also focused on cervical internal fixation products and
its R&D pipeline emphasizes both MAS and motion preservation.
NuVasive cautions you that statements included in this press release that
are not a description of historical facts are forward-looking statements that
involve risks, uncertainties, assumptions and other factors which, if they do
not materialize or prove correct, could cause Company's results to differ
materially from historical results or those expressed or implied by such
forward-looking statements. The potential risks and uncertainties that could
cause actual growth and results to differ materially include, but are not
limited to: the risk that the Company's revenue or profitability projections
may prove incorrect because of unexpected difficulty in generating sales or
achieving anticipated profitability; the risk that Company may encounter
unanticipated difficulty integrating the Osteocel product into its product
line; the risk that the Company may be unable to generate expected revenues or
profitability from Osteocel; the uncertain process of seeking regulatory
approval or clearance for Company's products or devices, including risks that
such process could be significantly delayed; the possibility that the FDA may
require significant changes to Company's products or clinical studies; the
risk that products may not perform as intended and may therefore not achieve
commercial success; the risk that competitors may develop superior products or
may have a greater market position enabling more successful commercialization;
the risk that additional clinical data may call into question the benefits of
Company's products to patients, hospitals and surgeons; and other risks and
uncertainties more fully described in Company's press releases and periodic
filings with the Securities and Exchange Commission. Company's public filings
with the Securities and Exchange Commission are available at www.sec.gov.
Company assumes no obligation to update any forward-looking statement to
reflect events or circumstances arising after the date on which it was made.
NuVasive, Inc.
Unaudited Condensed Consolidated Statement of Operations
(in thousands, except per share data)
Three Months Ended Six Months Ended
June 30, June 30,
2008 2007 2008 2007
Revenues $57,417 $35,618 $108,601 $68,838
Cost of goods sold 9,5716,71018,666 12,417
Gross Profit 47,846 28,90889,935 56,421
Operating expenses:
Sales, marketing and administrative 42,099 28,02781,416 56,067
Research and development 6,4265,92513,402 11,677
In-process research and development -- 4,176 -
Total operating expenses 48,525 33,95298,994 67,744
Interest and other income, net1841,628 9103,487
Net loss$(495) $(3,416) $(8,149) $(7,836)
Net loss per share:
Basic and diluted$(0.01) $(0.10) $(0.23) $(0.23)
Weighted average shares - basic and
diluted 35,663 34,65435,543 34,485
Stock-based compensation is included
in operating expenses in the
following categories:
Sales, marketing and administrative $4,538 $2,894$9,042 $5,522
Research and development610 575 1,2561,091
$5,148 $3,469 $10,298 $6,613
NuVasive, Inc.
Condensed Consolidated Balance Sheets
(in thousands)
June 30, December 31,
2008 2007
Assets (unaudited)
Current assets:
Cash and cash equivalents $136,224 $61,915
Short-term investments72,74619,247
Accounts receivable, net 32,52827,496
Inventory, net52,18536,280
Prepaid expenses and other current
assets2,947 1,240
Total current assets 296,630 146,178
Property and equipment, net of
accumulated depreciation 64,87643,538
Intangible assets, net of accumulated
amortization 25,95524,496
Long-term marketable securities 56,745 8,536
Other assets 9,254 2,939
Total assets $453,460 $225,687
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable and accrued liabilities $20,012 $13,839
Accrued payroll and related expenses 10,79312,075
Royalties payable 2,092 2,076
Total current liabilities 32,89727,990
Senior convertible notes 230,000 -
Long-term liabilities 590 1,119
Commitments and contingencies
Stockholders' equity:
Common stock, 70,000 shares
authorized 35,794 and 35,330 issued
and outstanding at June 30, 2008 and
December 31, 2007, respectively 3635
Additional paid-in capital 366,150 364,469
Accumulated other comprehensive loss (84) 54
Accumulated deficit (176,129) (167,980)
Total stockholders' equity 189,973 196,578
Total liabilities and stockholders'
equity $453,460 $225,687
NuVasive, Inc.
Condensed Consolidated Statements of Cash Flows
(unaudited and in thousands)
Six Months Ended June 30,
2008 2007
Operating activities:
Net loss$(8,149) $(7,836)
Adjustments to reconcile net loss to
net cash used in operating activities:
Depreciation and amortization 8,449 5,933
Stock-based compensation 10,298 6,613
In-process research and development 4,176 -
Other non-cash adjustments312 1,179
Changes in operating assets and liabilities:
Accounts receivable (5,044) (4,621)
Inventory (16,496) (8,868)
Prepaid expenses and other current assets(1,707) (39)
Accounts payable and accrued liabilities 3,361 1,926
Accrued payroll and related expenses (1,282) (421)
Net cash used in operating activities(6,082) (6,134)
Investing activities:
Cash paid for pedicle screw technology (6,256)
Cash paid for acquisition of Radius
Medical LLC- (6,970)
Purchases of property and equipment (25,686) (8,527)
Sales of short-term investments 19,30079,050
Purchases of short-term investments (72,799) (49,580)
Sales of long-term investments3,500 6,000
Purchases of long-term investments (51,709) (13,991)
Other assets543 5
Net cash provided by (used in)
investing activities (133,107)5,987
Financing activities:
Payment of long-term liabilities (300) (300)
Issuance of Senior Convertible Notes222,414 -
Purchase of convertible note hedges (45,758) -
Sale of warrants 31,786 -
Issuance of common stock 5,356 3,189
Net cash provided by financing activities 213,498 2,889
Increase in cash and cash equivalents74,309 2,742
Cash and cash equivalents at
beginning of period 61,91541,476
Cash and cash equivalents at end of period $136,224 $44,218
Contact:Investors:
Kevin C. O'BoyleNick Laudico/Zack Kubow
EVP & Chief Financial Officer The Ruth Group
NuVasive, Inc. 646-536-7030/7020
858-909-1800nlaudico@theruthgroup.com
investorrelations@nuvasive.com zkubow@theruthgroup.com
Media:
Jason Rando
The Ruth Group
646-536-7025
jrando@theruthgroup.com
SOURCE NuVasive, Inc.
